Drugs /
amg 509
Back to Drugs List
Overview
NCI Definition [1]:
A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, AMG 509 targets and binds to the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response
Clinical Trials
Amg 509 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating amg 509, 1 is phase 1 (1 open).
Prostate adenocarcinoma is the most common disease being investigated in amg 509 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
